HLA class I antigen down-regulation in primary laryngeal squamous cell carcinoma lesions as a poor prognostic marker

Cancer Research

Volumn 66, Issue 18, 2006, Pages 9281-9289

  Ogino, Takeshi ^a   Shigyo, Hiroshi ^a   Ishii, Hideyuki ^a   Katayama, Akihiro ^a,b   Miyokawa, Naoyuki ^a   Harabuchi, Yasuaki ^a   Ferrone, Soldano ^b  

^a ASAHIKAWA MEDICAL COLLEGE   (Japan)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALNEXIN; CALRETICULIN; HLA ANTIGEN; PROTEASOME; PROTEIN LMP2; TAPASIN; TRANSPORTER ASSOCIATED WITH ANTIGEN PROCESSING 1; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; CD8+ T LYMPHOCYTE; CELL INFILTRATION; DOWN REGULATION; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LARYNX CANCER; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; SURVIVAL;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTIBODY SPECIFICITY; ANTIGEN PRESENTATION; CARCINOMA, SQUAMOUS CELL; CD8-POSITIVE T-LYMPHOCYTES; CYSTEINE ENDOPEPTIDASES; DOWN-REGULATION; FEMALE; HLA-A ANTIGENS; HUMANS; LARYNGEAL NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 33749504503     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-06-0488     Document Type: Article

References (48)

1. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 2002;3:991-8.
2. Marincola FM, Jaffee EM, Hicklin DJ, Ferrone S. Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance. Adv Immunol 2000;74:181-273.
3. Hicklin DJ, Marincola FM, Ferrone S. HLA class I antigen downregulation in human cancers: T-cell immunotherapy revives as old story. Mol Med Today 1999;5:178-86.
4. Chang CC, Campoli M, Ferrone S. HLA class I antigen expression in malignant cells: why does it not always correlate with CTL-mediated lysis? Curr Opin Immunol 2004;16:644-50.
5. Ruiz-Cabello F, Lopez-Nevot MA, Gutierrez J, et al. Phenotypic expression of histocompatibility antigens in human primary tumours and metastases. Clin Exp Metastasis 1989;7:213-26.
6. Esteban F, Concha A, Delgado M, Perez-Ayala M, Ruiz-Cabello F, Garrido F. Lack of MHC class I antigens and tumour aggressiveness of the squamous cell carcinoma of the larynx. Br J Cancer 1990;62:1047-51.
7. Houck JR, Sexton FM, Zajdel G. HLA class I and class II antigen expression on squamous cell carcinoma of head and neck. Arch Otolaryngol Head Neck Surg 1990;116:1181-5.
8. Mattijssen V, De Mulder PH, Schalkwijk L, Manni JJ, Hof-Grootenboer BV, Ruiter DJ. HLA antigen expression in routinely processed head and neck squamous cell carcinoma primary lesions of different sites. Int J Cancer Suppl 1991;6:95-100.
9. Vora AR, Rodgers S, Parker AJ, Start R, Rees RC, Murray AK. An immunohistochemical study of altered immunomodulatory molecule expression in head and neck squamous cell carcinoma. Br J Cancer 1997;76:836-44.
10. Feenstra M, Rozemuller E, Duran K, et al. Mutation in the β2m gene is not a frequent event in head and neck squamous cell carcinoma. Hum Immunol 1999;60:697-706.
11. Ogino T, Bandoh N, Hayashi T, Miyokawa N, Harabuchi Y, Ferrone S. Association of tapasin and HLA class I antigen down-regulation in primary maxillary sinus squamous cell carcinoma lesions with reduced survival of patients. Clin Cancer Res 2003;9:4043-51.
12. Esteban F, Concha A, Huelin C, et al. Histocompatibility antigens in primary and metastatic squamous cell carcinoma of the larynx. Int J Cancer 1989;15:436-42.
13. Lopez-Nevot MA, Esteban F, Ferron A, et al. HLA class I gene expression on human primary tumours and autologous metastases: demonstration of selective losses of HLA antigens on colorectal, gastric and laryngeal carcinomas. Br J Cancer 1989;59:221-6.
14. Esteban F, Redondo M, Delgado M, Garrido F, Ruiz-Cabello F. MHC class I antigens and tumour-infiltrating leucocytes in laryngeal cancer: long-term follow-up. Br J Cancer 1996;74:1801-4.
15. Dworacki G, Kruk-Zagajewska A, Jezewska E, Sikora J, Zeromski J. Tumor infiltrating lymphocytes in HLA+ and HLA- laryngeal cancer-quantitative approach. Arch Immunol Ther Exp (Warsz) 1999;47:161-8.
16. Cabrera T, Salinero J, Fernandez MA, Garrido A, Esquivias J, Garrido F. High frequency of altered HLA class I phenotypes in laryngeal carcinomas. Hum Immunol 2000;61:499-506.
17. Cresswell P. Antigen processing and presentation. Immunol Rev 2005;207:5-313.
18. Chang CC, Campoli M, Ferrone S. Classical and non-classical HLA class I antigen and NK cell activating ligand changes in malignant cells: current challenges and future directions. Adv Cancer Res 2005;93:189-234.
19. Ogino T, Wang X, Kato S, Miyokawa N, Harabuchi Y, Ferrone S. Endoplasmic reticulum chaperone-specific monoclonal antibodies for flow cytometry and immunohistochemical staining. Tissue Antigens 2003;62:385-93.
20. Bandoh N, Ogino T, Cho HS, et al. Development and characterization of human constitutive proteasome and immunoproteasome subunit-specific monoclonal antibodies. Tissue Antigens 2005;66:185-94.
21. Wang X, Campoli M, Cho HS, et al. A method to generate antigen-specific mAb capable of staining formalin-fixed paraffin-embedded tissue sections. J Immunol Methods 2005;299:139-51.
22. Stam NJ, Spits H, Ploegh HL. Monoclonal antibodies raised against denatured HLA-B locus heavy chains permit biochemical characterization of certain HLA-C locus products. J Immunol 1986;137:2299-306.
23. Lampson LA, Fisher CA, Whelan JP. Striking paucity of HLA-A, B, C and β2-microglobulin on human neuroblastoma cell lines. J Immunol 1983;130:2471-8.
24. Perosa F, Luccarelli G, Prete M, Favoino E, Ferrone S, Dammacco F. β2-Microglobulin-free HLA class I heavy chain epitope mimicry by monoclonal antibody HC-10-specific peptide. J Immunol 2003;171:1918-26.
25. Garrido F, Cabrera T, Accolla RS, et al. HLA and cancer: 12th International Histocompatibility Workshop Study In: Charron D, editor. HLA. Genetic diversity of HLA, vol. 1. Functional and medical implication. Paris. EDK; 1997. p. 445-52.
26. Fisher LD, van Belle G. Biostatistics. A methodology for the health sciences. New York: John Wiley & Sons; 1993.
27. Chatterjee S, Hadi AS. Regression analysis by example, 2nd edition, New York: John Wiley & Sons; 1999.
28. Kaplan EL, Meier P. Nonparametric estimation from incomplete observation. J Am Stat Assoc 1958;53:457-81.
29. Cox DR. Regression models and life tables. J R Stat Soc B (Lond) 1972;34:187-202.
30. Delp K, Momburg F, Hilmes C, Huber C, Seliger B. Functional deficiencies of components of the MHC class I antigen pathway in human tumors of epithelial origin. Bone Marrow Transplant 2000;25:S88-95.
31. Corrias MV, Occhino M, Croce M, De Ambrosis A, Pistillo MP, Bocca P. Lack of HL A-class I antigens in human neuroblastoma cells: analysis of its relationship to TAP and tapasin expression. Tissue Antigens 2001;57:110-7.
32. Seliger B, Schreiber K, Delp K, Meissner M, Hammers S, Reichert T. Downregulation of the constitutive tapasin expression in human tumor cells of distinct origin and its transcriptional upregulation by cytokines. Tissue Antigens 2001;57:39-45.
33. Seliger B, Ritz U, Abele R, Bock M, Tampe R, Sutter G. Immune escape of melanoma: first evidence of structural alterations in two distinct components of the MHC class I antigen processing pathway. Cancer Res 2001;61:8647-50.
34. Chen HL, Gabrilovich D, Tampe R, Girgis KR, Nadaf S, Carbone DP. A functionally defective allele of TAP1 results in loss of MHC class I antigen presentation in a human lung cancer. Nat Genet 1996;13:210-3.
35. Atkins D, Breuckmann A, Schmahl GE, Binner P, Ferrone S, Krummenauer F. MHC class I antigen processing pathway defects, ras mutations and disease stage in colorectal carcinoma. Int J Cancer 2004;109:265-73.
36. Seliger B, Atkins D, Bock M, Ritz U, Ferrone S, Huber C. Characterization of human lymphocyte antigen class I antigen-processing machinery defects in renal cell carcinoma lesions with special emphasis on transporter-associated with antigen-processing down-regulation. Clin Cancer Res 2003;9:1721-7.
37. Kageshita T, Hirai S, Ono T, Hicklin DJ, Ferrone S. Down-regulation of HLA class I antigen-processing molecules in malignant melanoma: association with disease progression. Am J Pathol 1999;154:745-54.
38. Weinman EC, Roche PC, Kasperbauer JL, et al. Characterization of antigen processing machinery and survivin expression in tonsillar squamous cell carcinoma. Cancer 2003;97:2203-11.
39. Restifo NP, Esquivel F, Asher AL, Stotter H, Barth RJ, Bennink JR. Defective presentation of endogenous antigens by a murine sarcoma. Implications for the failure of an anti-tumor immune response. J Immunol 1991;147:1453-9.
40. Seliger B, Hohne A, Jung D, Kallfelz M, Knuth A, Jaeger E. Expression and function of the peptide transporters in escape variants of human renal cell carcinomas. Exp Hematol 1997;25:608-14.
41. Alimonti J, Zhang QJ, Gabathuler R, Reid G, Chen SS, Jefferies WA. TAP expression provides a general method for improving the recognition of malignant cells in vivo. Nat Biotechnol 2000;18:515-20.
42. Lankat-Buttgereit B, Tampe R. The transporter associated with antigen processing: function and implications in human diseases. Physiol Rev 2000;82:187-204.
43. Lehner PJ, Surman MJ, Cresswell P. Soluble tapasin restores MHC class I expression and function in the tapasin-negative cell line.220. Immunity 1998;8:221-31.
44. Van Kaer L, Ashton-Rickardt PG, Eichelberger M, Gaczynska M, Nagashima K, Rock KL. Altered peptidase and viral-specific T cell response in LMP2 mutant mice. Immunity 1994;1:533-41.
45. Benham AM, Neefjes JJ. Proteasome activity limits the assembly of MHC class I molecules after IFN-γ stimulation. J Immunol 1997;159:5896-904.
46. Singal DP, Ye M, Qiu X. Molecular basis for lack of expression of HLA class I antigens in human small-cell lung carcinoma cell lines. Int J Cancer 1996;68:629-36.
47. Kageshita T, Hirai S, Ono T, Ferrone S. Comparison of the reactivity of frozen and formalin-fixed, paraffin-embedded sections of melanoma lesions with anti-HLA class I mAb. In: Charron D, editor. HLA. Genetic diversity of HLA. Functional and medical implication. vol. II. EDK. Paris, France. 1997. p. 737-9.
48. Hosch SB, Izbicki JR, Pichlmeier U, et al. Expression and prognostic significance of immunoregulatory molecules in esophageal cancer. Int J Cancer 1997;74:582-7.